GGrantIndex
← Leaderboards

Jonathan R Sporn

Massachusetts General Hospital

$711,029
Attributed
$711,029
Total exposure
7
Grants
0
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding mix

By agency

NIH$711,029 · 7

By mechanism

M01$711,029 · 7

Top collaborators

No co-investigators on record.

Most similar at Massachusetts General Hospital

Same institution · by research overlap

Others in their field

Top investigators on “Human Subject

Research focus

Human SubjectClinical ResearchHuman Therapy EvaluationBreast NeoplasmsFemaleSerology /SerodiagnosisBiomarkerNeoplasm /Cancer VaccineNeoplasm /Cancer ImmunotherapyTumor AntigensClinical Trial Phase ICell TransplantationB Cell LymphomaCellular ImmunityCell Mediated CytotoxicityCell LineAntineoplasticsEnzyme Linked Immunosorbent AssayClinical TrialsFibroblast Growth FactorCytotoxic T LymphocyteDiagnosis Design /EvaluationChronic Lymphocytic LeukemiaBone Neoplasms

Grant awards (38)

Herbal Therapy for Hotflashes$5,540
M01 · FY2004 · RR
PYRIDOSTIGMINE INDUCED GROWTH HORMONE RESPONSE IN MOOD DISORDERS$200,768
M01 · FY2002 · RR
PYRIDOSTIGMINE INDUCED GROWTH HORMONE RESPONSE IN MOOD DISORDERS$200,768
M01 · FY2002 · RR
MONOCYTE/HER2 VACCINE IN BREAST AND OVARIAN CANCER PATIENTS$0
M01 · FY2002 · RR
IDENTIFICATION OF TUMOR SPECIFIC T LYMPHOCYTES FROM PERIPHERAL BLOOD OF CANCER$0
M01 · FY2002 · RR
TREATMENT OF INDOLENT B CELL LYMPHOMA &CLL PATIENTS W/ HEAT SHOCK PR$0
M01 · FY2002 · RR
FIBROBLAST GROWTH FACTOR AND BONE RESORPTION IN PATIENTS WITH BREAST CANCER$0
M01 · FY2002 · RR
PYRIDOSTIGMINE INDUCED GROWTH HORMONE RESPONSE IN MOOD DISORDERS$200,768
M01 · FY2001 · RR
TREATMENT OF INDOLENT B CELL LYMPHOMA &CLL PATIENTS W/ HEAT SHOCK PR$4,361
M01 · FY2001 · RR
IDENTIFICATION OF TUMOR SPECIFIC T LYMPHOCYTES FROM PERIPHERAL BLOOD OF CANCER$4,361
M01 · FY2001 · RR
FIBROBLAST GROWTH FACTOR AND BONE RESORPTION IN PATIENTS WITH BREAST CANCER$4,361
M01 · FY2001 · RR
MONOCYTE/HER2 VACCINE IN BREAST AND OVARIAN CANCER PATIENTS$4,361
M01 · FY2001 · RR
MONOCYTE/HER2 VACCINE IN BREAST AND OVARIAN CANCER PATIENTS$0
M01 · FY2001 · RR
PYRIDOSTIGMINE INDUCED GROWTH HORMONE RESPONSE IN MOOD DISORDERS$0
M01 · FY2001 · RR
MONOCYTE/HER2 VACCINE IN BREAST AND OVARIAN CANCER PATIENTS$0
M01 · FY2001 · RR
FIBROBLAST GROWTH FACTOR AND BONE RESORPTION IN PATIENTS WITH BREAST CANCER$0
M01 · FY2001 · RR
FIBROBLAST GROWTH FACTOR AND BONE RESORPTION IN PATIENTS WITH BREAST CANCER$0
M01 · FY2001 · RR
IDENTIFICATION OF TUMOR SPECIFIC T LYMPHOCYTES FROM PERIPHERAL BLOOD OF CANCER$0
M01 · FY2001 · RR
IDENTIFICATION OF TUMOR SPECIFIC T LYMPHOCYTES FROM PERIPHERAL BLOOD OF CANCER$0
M01 · FY2001 · RR
TREATMENT OF INDOLENT B CELL LYMPHOMA &CLL PATIENTS W/ HEAT SHOCK PR$0
M01 · FY2001 · RR
TREATMENT OF INDOLENT B CELL LYMPHOMA &CLL PATIENTS W/ HEAT SHOCK PR$0
M01 · FY2001 · RR
TREATMENT OF INDOLENT B CELL LYMPHOMA &CLL PATIENTS W/ HEAT SHOCK PR$19,111
M01 · FY2000 · RR
MONOCYTE/HER2 VACCINE IN BREAST AND OVARIAN CANCER PATIENTS$19,111
M01 · FY2000 · RR
FIBROBLAST GROWTH FACTOR AND BONE RESORPTION IN PATIENTS WITH BREAST CANCER$19,111
M01 · FY2000 · RR
IDENTIFICATION OF TUMOR SPECIFIC T LYMPHOCYTES FROM PERIPHERAL BLOOD OF CANCER$19,111
M01 · FY2000 · RR
IDENTIFICATION OF TUMOR SPECIFIC T LYMPHOCYTES FROM PERIPHERAL BLOOD OF CANCER$4,361
M01 · FY2000 · RR
IDENTIFICATION OF TUMOR SPECIFIC T LYMPHOCYTES FROM PERIPHERAL BLOOD OF CANCER$4,361
M01 · FY2000 · RR
PYRIDOSTIGMINE INDUCED GROWTH HORMONE RESPONSE IN MOOD DISORDERS$575
M01 · FY2000 · RR
TREATMENT OF INDOLENT B CELL LYMPHOMA &CLL PATIENTS W/ HEAT SHOCK PR$0
M01 · FY2000 · RR
PYRIDOSTIGMINE INDUCED GROWTH HORMONE RESPONSE IN MOOD DISORDERS$0
M01 · FY2000 · RR
FIBROBLAST GROWTH FACTOR AND BONE RESORPTION IN PATIENTS WITH BREAST CANCER$0
M01 · FY2000 · RR
TREATMENT OF INDOLENT B CELL LYMPHOMA &CLL PATIENTS W/ HEAT SHOCK PR$0
M01 · FY2000 · RR
FIBROBLAST GROWTH FACTOR AND BONE RESORPTION IN PATIENTS WITH BREAST CANCER$0
M01 · FY2000 · RR
MONOCYTE/HER2 VACCINE IN BREAST AND OVARIAN CANCER PATIENTS$0
M01 · FY2000 · RR
MONOCYTE/HER2 VACCINE IN BREAST AND OVARIAN CANCER PATIENTS$0
M01 · FY2000 · RR
Tumor antigen &APC based breast cancer vaccine phase I/II trial$0
M01 · FY2000 · RR
Tumor antigen &APC based breast cancer vaccine phase I/II trial$0
M01 · FY2000 · RR
Tumor antigen &APC based breast cancer vaccine phase I/II trial$0
M01 · FY2000 · RR